Advanced search
Publication Cover
International Journal of Radiation Biology Volume 97, 2021 - Issue 9
Submit an article Journal homepage
1,930
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

CyberKnife radiation therapy as a platform for translational mouse studies

Martha Kiljana Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Sabrina Weilb Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany;d Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, GermanyView further author information
,
Andres Vásquez-Torresa Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Meike Hetticha Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Marimel Mayera Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Olta Ibrulib Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany;d Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, GermanyView further author information
,
Matthias Reinscheida Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Isabelle Heßelmanna Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Jiali Caia Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Li-na Niua Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Yagmur Sahbazb Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany;d Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, GermanyView further author information
,
Christian Bauesa Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;d Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, GermanyView further author information
,
Wolfgang W. Bausa Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Florian Kampa Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Simone Marnitza Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyView further author information
,
Grit S. Herter-Sprieb Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany;d Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, GermanyCorrespondence[email protected]
View further author information
&
Jan M. Hertera Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;b Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany;c Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, GermanyCorrespondence[email protected]
View further author information
 show all
Pages 1261-1269 | Received 29 Oct 2020, Accepted 12 May 2021, Published online: 23 Jun 2021

References

  • Adler JR, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. 1997. The CyberKnife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 69(1–4 Pt 2):124–128.
  • Asna N, Livoff A, Batash R, Debbi R, Schaffer P, Rivkind T, Schaffer M. 2018. Radiation therapy and immunotherapy-a potential combination in cancer treatment. Curr Oncol. 25(5):e454–e460.
  • Baskar R, Lee KA, Yeo R, Yeoh KW. 2012. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 9(3):193–199.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
  • Citrin DE. 2017. Recent developments in radiotherapy. N Engl J Med. 377(22):2200–2201.
  • Du J, Su S, Li H, Shao J, Meng F, Yang M, Qian H, Zou Z, Qian X, Liu B. 2017. Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer. Exp Ther Med. 14(6):5711–5716.
  • Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, Gaipl US. 2014. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 63(1):29–36.
  • Gerszten PC, Burton SA, Ozhasoglu C. 2007. CyberKnife radiosurgery for spinal neoplasms. Prog Neurol Surg. 20:340–358.
  • Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et al. 2019. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 37(18):1558–1565.
  • Herter JM, Rossaint J, Spieker T, Zarbock A. 2014. Adhesion molecules involved in neutrophil recruitment during sepsis-induced acute kidney injury. J Innate Immun. 6(5):597–606.
  • Herter-Sprie GS, Korideck H, Christensen CL, Herter JM, Rhee K, Berbeco RI, Bennett DG, Akbay EA, Kozono D, Mak RH, et al. 2014. Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun. 5:5870.
  • Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, et al. 2016. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 1(9):e87415.
  • Herter-Sprie GS, Kung AL, Wong KK. 2013. New cast for a new era: preclinical cancer drug development revisited. J Clin Invest. 123(9):3639–3645.
  • Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, et al. 2018. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 4(1):e173501.
  • Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65(22):10280–10288.
  • Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. 2013. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 24(5):589–602.
  • Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, et al. 2016. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76(5):999–1008.
  • Liu J, Zhou J, Wu M, Hu C, Yang J, Li D, Wu P, Chen Y, Chen P, Lin S, et al. 2019. Low-dose total Body irradiation can enhance systemic immune related response induced by hypo-fractionated radiation. Front Immunol. 10:317.
  • Loizides C, Iacovides D, Hadjiandreou MM, Rizki G, Achilleos A, Strati K, Mitsis GD. 2015. Model-based tumor growth dynamics and therapy response in a mouse model of de novo carcinogenesis. PLoS One. 10(12):e0143840.
  • Lwin TM, Hoffman RM, Bouvet M. 2018. Advantages of patient-derived orthotopic mouse models and genetic reporters for developing fluorescence-guided surgery. J Surg Oncol. 118(2):253–264.
  • Muacevic A, Staehler M, Drexler C, Wowra B, Reiser M, Tonn JC. 2006. Technical description, phantom accuracy, and clinical feasibility for fiducial-free frameless real-time image-guided spinal radiosurgery. J Neurosurg Spine. 5(4):303–312.
  • Nomura R, Suzuki I. 2011. CyberKnife radiosurgery–present status and future prospect. Brain Nerve. 63(3):195–202.
  • Qiu W, Su GH. 2013. Development of orthotopic pancreatic tumor mouse models. Methods Mol Biol. 980:215–223.
  • Schweikard A, Shiomi H, Adler J. 2005. Respiration tracking in radiosurgery without fiducials. Int J Med Robot. 1(2):19–27.
  • Sevenich L. 2019. Turning "cold" into "hot" tumors-opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers. Front Oncol. 9:163.
  • Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, et al. 2015. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5(8):860–877.
  • Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, et al. 2018. Mutations and PD-1 Inhibitor Resistance in. Cancer Discov. 8(7):822–835.
  • Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 37(1):48–55.
  • Takimoto CH. 2001. Why drugs fail: of mice and men revisited. Clin Cancer Res. 7(2):229–230.
  • Talmadge JE, Singh RK, Fidler IJ, Raz A. 2007. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 170(3):793–804.
  • Tillner F, Thute P, Bütof R, Krause M, Enghardt W. 2014. Pre-clinical research in small animals using radiotherapy technology–a bidirectional translational approach. Z Med Phys. 24(4):335–351.
  • Tubin S, Khan MK, Salerno G, Mourad WF, Yan W, Jeremic B. 2019. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment. Radiat Oncol. 14(1):212.
  • Tubin S, Popper HH, Brcic L. 2019. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol. 14(1):21.
  • Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. 2017. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 8:15618.
  • Verhaegen F, Dubois L, Gianolini S, Hill MA, Karger CP, Lauber K, Prise KM, Sarrut D, Thorwarth D, Vanhove C, et al. 2018. ESTRO ACROP: technology for precision small animal radiotherapy research: optimal use and challenges. Radiother Oncol. 126(3):471–478.
  • Verhaegen F, Granton P, Tryggestad E. 2011. Small animal radiotherapy research platforms. Phys Med Biol. 56(12):R55–83.
  • Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. 2018. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 9:185.
  • Zhao X, Li L, Starr TK, Subramanian S. 2017. Tumor location impacts immune response in mouse models of colon cancer. Oncotarget. 8(33):54775–54787.
  • Zuppone S, Bresolin A, Spinelli AE, Fallara G, Lucianò R, Scarfò F, Benigni F, Di Muzio N, Fiorino C, Briganti A, et al. 2020. Pre-clinical research on bladder toxicity after radiotherapy for pelvic cancers: state-of-the art and challenges. Front Oncol. 10:527121.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.